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HER-2 = human epidermal growth factors receptor-2; PDK1 = phosphatidylinositol-3,4,5-trisphosphate-dependent kinase; PI3-K = phosphoinosi-
tide 3-kinase; siRNA = short interfering RNA.
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Introduction
A recent study by Arboleda and colleagues has addressed
the role of Akt2 in metastasis with the use of human breast
and ovarian cancer cell lines [1]. This study revealed that
Akt2 was sufficient to mediate phosphoinositide 3-kinase
(PI3-K)-dependent effects on the metastatic process in
these cells. Akt2, also known as PKBβ, is one of three iso-
forms of Akt [2]. It is a serine/threonine protein kinase and a
downstream target of PI3-K. The mechanism of action is the
same for all Akt isoforms: activation is initiated by growth
factors binding to their transmembrane receptors, which in
turn activate PI3-K either directly or indirectly (via Ras).
PI3-K then catalyses the conversion of phosphatidylinositol-
4,5-bisphosphate to phosphatidylinositol-3,4,5-trisphos-
phate, a second messenger that is essential for the
recruitment of Akt to the plasma membrane. Once
anchored, Akt can be phosphorylated and activated by
phosphatidylinositol-3,4,5-trisphosphate-dependent kinase
(PDK1). Activated Akt promotes the transcription of a range
of genes, in particular those involved in cellular transforma-
tion and proliferation [3,4]. The PI3-K/Akt signalling pathway
contributes to many types of human malignancies [5–7].
During the last few years, specific signalling roles for indi-
vidual Akt isoforms have begun to emerge [5,8–10].
Although much attention has focused on understanding the
role of Akt1 in cell survival and proliferation, the study by
Arboleda and colleagues [1] has highlighted the impor-
tance of Akt2 in metastasis in breast and ovarian cancer
cells. This work reinforces the idea that members of the Akt
family have distinct functional roles in tumour progression.
Akt2 and the metastatic process
The tumorigenicity of Akt2 is evident. Activation of Akt2
has been shown in ovarian [10] and breast [8] cancers.
Work performed in NIH 3T3 fibroblast cells, in which Akt2
was exogenously expressed, showed malignant transfor-
mation [11], and PANC1 pancreatic cancer cells express-
ing antisense Akt2 RNA could suppress invasion and
tumour formation in nude mice [12]. However, the effect of
Akt2  in vivo has not previously been investigated.
Arboleda and colleagues approached this by generating
stable breast and ovarian cancer cell lines expressing the
full-length Akt2 cDNA. They noted that the Akt2-overex-
pressing cells were able to migrate readily through
matrigel and could survive longer than the parental control
cell line under nutrient-poor conditions. Morphological
changes, such as lamellipodium formation and membrane
ruffling, which are features of migrating cells [13], were
also observed. Because part of the metastatic process
involves the migration of detached cancer cells from the
primary site, perhaps it was these observations that
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Metastasis in breast cancer significantly increases morbidity and mortality. The 5-year survival rate
reduces from 90% for localised disease to about 20% once metastasis has taken place. The
phosphoinositide 3-kinase/Akt signalling pathway has an important role in cell motility, invasion and
metastasis. However, the precise contribution of the Akt kinase family members, Akt1, Akt2 and Akt3,
in mediating these processes is unclear. The possibility that they have distinct functions in tumour
progression is particularly interesting.
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prompted the investigators to explore the role of Akt2 in
metastasis.
Akt2 effects in vitro
In vitro work performed by Arboleda and colleagues on
cell adhesion and invasion employed standard assays [1].
The main finding was that the Akt2 transfectants resulted
in increased attachment and invasion through collagen IV.
These properties were associated with an increased
expression of β1-integrins, which are cell surface recep-
tors for extracellular matrix and basement membrane com-
ponents such as collagen IV and laminin [14]. Neutralising
antibodies against β1-integrin were able to reduce inva-
sion significantly. These experiments were performed in
one clonal cell line, Akt2-overexpressing MDA-MB-435
breast cancer cells. It would have been interesting to
determine whether other cancer cell types that have high
levels of endogenous Akt2, for example OVCAR3 cells,
gave similar results. Similarly, it would have been interest-
ing to assess the possibility that other Akt isoforms also
contributed to the elevated β1-integrin levels. Neverthe-
less, the specific importance of Akt2 in mediating the
metastatic process in breast cancer cells in vitro was con-
firmed by showing that cells transfected with Akt1 and
Akt3 had only minor effects in invasion assays [1].
The caveat in these confirmation studies was that
Arboleda and colleagues used MDA-MB-435 HER-2 cells.
The observations made might therefore not have reflected
the invasive potential solely attributable to Akt2. This is
because overexpression of human epidermal growth
factors receptor-2 (HER-2)/neu has been shown to corre-
late with elevated expression of Akt2 and increased Akt
kinase activity [15]. It is therefore possible that the effects
of exogenous Akt2 expression on invasion of these cells
were enhanced by the contribution of HER-2/neu or that
HER-2/neu overexpression contributed to the activation of
the other Akt isoforms that led to the increased invasion
by Akt2 overexpression [1]. Extending these experiments
to include a number of cellular backgrounds would ensure
that the observations made were not cell-type specific.
Akt2 effects in vivo
A demonstration of increased adhesion and invasion does
not necessarily translate to an ability for cells to metasta-
sise, because these are only two steps in a complex
process in which many genes are involved. The contribu-
tion of a particular molecule to metastasis can only be
convincingly proven by performing studies in vivo.
Arboleda and colleagues showed that Akt2-overexpress-
ing breast cancer cells resulted in the successful forma-
tion of metastases when injected into nude mice,
suggesting that Akt2 is likely to mediate the regulation of a
large number of metastatic genes. The Akt2 transfectants
developed multiple macroscopic and microscopic
nodules. The metastases spread to several distant sites;
these retained Akt2 expression, as confirmed by immuno-
histochemistry. The parental cells, in contrast, generated
one or two localised but larger tumour masses [1]. The dif-
ference in size was correlated with an increased expres-
sion of β1-integrin in the Akt2 transfectants. It has already
been shown that β1-integrins can mediate cell migration
by interacting with the extracellular matrix components and
reducing cell–cell interaction [16]. It therefore follows that
the increased expression of β1-integrin could contribute to
the more widespread metastases and smaller tumours
observed in the Akt2 transfectants.
The role of Akt2 in vivo was confirmed by using a kinase-
dead (inactive) Akt2 mutant (K181M-Akt2), which signifi-
cantly reduced not only metastases but also tumour growth
[1]. This study was performed in xenografts derived from
SKOV3(K181M)Akt2 cells (an ovarian cancer cell line over-
expressing kinase-dead Akt2) [1]. Unfortunately, Arboleda
and colleagues did not take the opportunity to compare the
effects of this mutant in vivo in Akt1-transfected or Akt3-
transfected cells. The sequences surrounding the regulatory
phosphorylation sites within the kinase domain of Akt2 are
highly conserved between all Akt isoforms [17], and it is
possible that the K181M-Akt2 dominant-negative could
affect other Akt isoforms. Details of the specificity of the
K181M-Akt2 construct and the Akt isoform expression
pattern in the SKOV3(K181M)Akt2 cells would therefore
have enabled Arboleda and colleagues to make more defini-
tive conclusions about the role of Akt2. In addition, insight
could potentially have been gained into which isoform, if
any, commands the principal role in metastasis by using
short interfering RNA (siRNA) technology.
One would speculate from the published data that both
Akt1 and Akt3 have a role in the metastatic process,
because Akt1 is highly oncogenic [18] and has been
shown to increase migration and invasion of HT1080
human fibrosarcoma cells [19] as well as mouse mammary
epithelial cells [20], and Akt3 expression has been
observed in aggressive tumours [9], implying a high prob-
ability of transformation to a metastatic phenotype. In
support of this, Arboleda and colleagues also observed
that both Akt1 and Akt3 had better invasive ability than the
parental cells, although to a smaller extent than Akt2 [1].
Akt2 mediates PI3-K-dependent effects
Several notable points about Akt2 and invasion in breast
cancer are highlighted in this study. First, Akt2 needs to be
activated for metastasis to develop. MDA-MB-435 cells
expressing a kinase-dead Akt2 mutant had diminished inva-
sion potential and were unable to form tumours or metas-
tases  in vivo. The importance of Akt activation in the
metastatic process was previously shown in ovarian [10]
and pancreatic [21] cancer cells. Second, Akt2 cooperates
with other oncogenic signals to mediate metastatic
processes. Overexpression of Akt2 in normal cells pro-57
duced no effects [1]. Indeed, Akt2 was not detected in
normal tissue or benign tumour samples [22], whereas high
levels were observed in stage III and IV ovarian cancers
[10]. Third, PI3-K and other components of the PI3-K/Akt
pathway can mediate cell invasion. This was demonstrated
by the observation that overexpression of p110α (one of the
catalytic subunits of PI3-K) or PDK1 could induce cell inva-
sion analogous to that observed for Akt2 overexpression,
and expression of phosphatase and tensin homologue
deleted on chromosome ten (PTEN, a tumour suppressor
protein that dephosphorylates PI3-K) had the opposite
effect on cell invasion [1]. Furthermore, wortmannin and
LY294002, which are both inhibitors of PI3-K, blocked cell
attachment and invasion in Akt2-overexpressing cells.
Of particular interest is a recent study using Akt1, Akt2 and
p110β (one of the PI3-K catalytic subunits) siRNAs in HeLa
cells to determine their relative effects on cell growth [23].
Although p110β siRNA and inhibitors of PI3-K completely
inhibited cell growth of HeLa cells on matrigel, neither Akt1
nor Akt2 siRNA had any significant effect. It is therefore
possible that not only are there distinct and overlapping
roles for members of the Akt family in tumour progression,
but these functions might also be cell-type specific.
Conclusions
The link between Akt2 and breast cancer has been eluci-
dated in several studies [15,22], but the effect of Akt2 on
tumour metastasis and growth in vivo has not been
demonstrated until recently [1]. In an interesting study,
Arboleda and colleagues have established a role for Akt2
in metastasis of breast cancer cells and have clearly
shown the importance of the Akt pathway in the metasta-
tic process, both in vitro and in vivo. Knowledge of the
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